Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: cardiologists, internists

+ Sample video: contact me for sample video

+ Information:

* WARNING: This is the full version, not the incomplete one that many other websites are selling cheaply.

12-Jun-2026 to 13-Jun-2026

This comprehensive heart failure and cardiomyopathy program brings together leading experts to explore the latest breakthroughs shaping cardiovascular care. Designed for clinicians across the spectrum of practice, the course delivers cutting-edge insights into HFrEF, genetic and inflammatory cardiomyopathies, metabolic drivers of heart failure, and the rapidly evolving landscape of precision medicine.

Participants will gain practical, evidence-based strategies for optimizing guideline-directed therapy, interpreting emerging clinical trials, and managing complex conditions such as cardiogenic shock, cardiac amyloidosis, and advanced heart failure requiring mechanical circulatory support or transplant evaluation.

With dedicated sessions on future innovations, multidisciplinary intersections, and real-world clinical challenges, this program equips learners with the knowledge and confidence to deliver timely, personalized, and high-quality care to patients with heart failure and cardiomyopathies.

Learning Objectives
Apply precision medicine principles to the evaluation and management of patients with heart failure across the EF spectrum, incorporating genetic, imaging, metabolic, and phenotypic data into individualized care plans.

• Integrate contemporary evidence since the 2022 guidelines in GDMT, devices, advanced therapies, and obesity/metabolic treatments into day-to-day clinical decision-making for HFrEF and HFpEF.

• Optimize systems of care for complex HF patients by implementing CKM models, population-health strategies, remote monitoring, and equitable access pathways to advanced heart failure therapies.

• Select and manage advanced and critical care therapies with greater precision, including temporary and durable mechanical circulatory support, ECMO configurations, and evolving antithrombotic and allocation strategies for LVAD and heart transplantation.

• Leverage emerging technologies and innovations such as AI, gene and regenerative therapies, and novel diagnostics to enhance early detection, risk stratification, and personalized treatment of cardiomyopathies and cardiac amyloidosis.

Target Audience
The course is directed toward physicians, physician assistants, nurse practitioners, nurses, and all healthcare providers with an interest in treating and managing patients with heart failure.

 

+ Topics:

• 01 GDMT in 2026 Beyond the Guidelines and into Practice
• 02 Towards Precision Medicine with Cardiac MRI for DCM
• 03 Genetic Testing What Every HF Clinician Needs to Know
• 04 Cardiac Sarcoidosis Across the EF Spectrum
• 05 Cardio-Oncology in the Advanced HF Clinic
• 06 Session 1 HFrEF, Genetic and Inflammatory Cardiomyopathy Q&A
• 07 CKM (cardio-kidney-metabolic) Care Models and Practical Implementation
• 08 Diet and Exercise as Therapeutic Interventions for HFpEF
• 09 Sex Differences in HFpEF Development and Management
• 10 Ambulatory PA Monitoring Who, When, How 11 When GDMT Isn’t Enough_ Recognizing Advanced HFrEF Before Its Too Late
• 12 Session 2 HF and Metabolic Health Q&A
• 13 HFrEF in the Device Era_ Rise of the Machines
• 14 The Promise of AI in HF From Risk Prediction to Workflow Integration
• 15 Gene Therapies The Future of HF Personalized Therapy
• 16 Implications of a CD36 Genetic Variant as a Cause of Cardiomyopathy
• 17 Metabolic Health as a Therapeutic Target for HFrEF
• 18 Session 3 Future Horizons in HF and the Cardiomyopathies Q&A
• 19 Ventricular Assist Devices 101
• 20 Heart Transplantation 101
• 21 Challenging Cases in GDMT Management
• 22 Diuresis Pathways Across the Spectrum of Care
• 23 Breakout Session 2 – Top Five Trials of 2025-26 Q&A
• 24 DIGIT-HF
• 25 VICTOR
• 26 SUMMIT and substudies
• 27 FINEARTS-HF and substudies, RE-DEFINE-HF
• 28 Neuregulin and Other Regenerative Pathways in HFrEF
• 30 Equitable Heart Failure Care in a CKM World
• 31 HF Population Health From Individual Patients to Networks of Care
• 32 Reframing HF_ Treating and Preventing the Syndrome, Its Causes, and Comorbid Conditions
• 33 Session 1 Heart Failure at Scale Q&A
• 34 Cardiogenic Shock in 2026 From Guidelines to Bedside
• 35 Precision Temporary MCS Devices When, How, and For Whom
• 36 ECMO Cannulation Strategy_ VA, VAV, LAVA and more
• 37 Personalizing Care for LVAD Recipients
• 38 Heart Allocation by Continuous Distribution Are We Nearly There Yet
• 39 Session 2 Shock and Advanced Therapies Q&A
• 40 Structural Which Patients with AS and HFrEF Benefit Most from TAVR
• 41 EP Which Patients with AF Most Benefit from Ablation
• 42 Surgery Which Patients with HF can Undergo CABG and Valve Surgery
• 43 AI in Action Practical Tools for the Heart Failure Clinician
• 44 New Insights Through Imaging and Tracers
• 45 Evolutions in TTR Therapies
• 46 Gene editing and TTR removal
• 47 AL Amyloid Conundrums (Case Based)
• 48 Educating Patients on an Amyloid Diagnosis
• 49 Amyloidosis and the Musculoskeletal System
• 50 Cardiac Amyloid Session Q&A
• Friday Session 1 – Updates in HF Epidemiology and Population Health
• Friday Session 2 HFrEF and EP Innovations
• Friday Session 3 – HFpEF and Pulmonary Hypertension
• Friday Session 4A- Meet the Clinical Trialists Concurrent Session
• Saturday Session 1- Cardiomyopathies amyloid, HCM, Sarcoid and HFrEF
• Saturday Session 2- MCS and TX
• Saturday Session 3- Cardiogenic shock and critical care